Skip to content

Study · Case report or series · n = 32 · 2000

6 results

[Effects of thymalin on blood coagulation and contents of proinflammatory and anti-inflammatory cytokines in patients with burns].

Kuznik BI, Vitkovskiĭ IuA, Budazhabon GB, Sizonenko VA

Vestnik khirurgii imeni I. I. Grekova1 Jan 2000

PMID11188814 (opens in a new tab)PepBankPUB-11188814
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In patients with severe burns, thymalin treatment was associated with resolution of disseminated intravascular coagulation.

    In plain wordsIn patients with severe burns, thymalin treatment was linked to resolution of widespread abnormal blood clotting.

    Peptide
    Thymalin
    Outcome
    DecreaseDisseminated intravascular coagulation
    Study

    n = 32

    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The authors share their experiences with treatment of 32 patients with burns of the III-IV degrees using an immunomodulator Thymalin which promoted liquidation of the syndrome of disseminated intravascular coagulation
  2. 02HumanCase report or seriesEfficacy outcome

    In patients with severe burns, thymalin treatment was associated with normalization of fibrinolysis.

    In plain wordsIn patients with severe burns, thymalin treatment was linked to normalization of blood clot breakdown.

    Peptide
    Thymalin
    Outcome
    Direction not reportedFibrinolysis
    Study

    n = 32

    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The authors share their experiences with treatment of 32 patients with burns of the III-IV degrees using an immunomodulator Thymalin which promoted liquidation of the syndrome of disseminated intravascular coagulation, normalization of fibrinolysis
  3. 03HumanCase report or seriesEfficacy outcome

    In patients with severe burns, thymalin treatment was associated with changes in pro-inflammatory cytokine content, with direction unspecified.

    In plain wordsIn patients with severe burns, thymalin treatment was linked to changes in inflammatory signaling proteins, with direction unspecified.

    Peptide
    Thymalin
    Outcome
    Direction not reportedPro-inflammatory cytokine content
    Study

    n = 32

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The authors share their experiences with treatment of 32 patients with burns of the III-IV degrees using an immunomodulator Thymalin which promoted liquidation of the syndrome of disseminated intravascular coagulation, normalization of fibrinolysis, influenced the content of pro-inflammatory and ant…
  4. 04HumanCase report or seriesEfficacy outcome

    In patients with severe burns, thymalin treatment was associated with changes in anti-inflammatory cytokine content, with direction unspecified.

    In plain wordsIn patients with severe burns, thymalin treatment was linked to changes in anti-inflammatory signaling proteins, with direction unspecified.

    Peptide
    Thymalin
    Outcome
    Direction not reportedAnti-inflammatory cytokine content
    Study

    n = 32

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The authors share their experiences with treatment of 32 patients with burns of the III-IV degrees using an immunomodulator Thymalin which promoted liquidation of the syndrome of disseminated intravascular coagulation, normalization of fibrinolysis, influenced the content of pro-inflammatory and ant…
  5. 05HumanCase report or seriesEfficacy outcome

    In patients with severe burns, thymalin treatment was associated with an average 5 days shorter time to first autodermoplasty.

    In plain wordsIn patients with severe burns, thymalin treatment was linked to an average 5 days shorter time to the first skin graft.

    Peptide
    Thymalin
    Outcome
    DecreaseTime to first autodermoplasty
    Study

    n = 32

    Outcome group
    Wound healing · Skin and wound
    Studied dose
    Dose not stated

    Measurements

    Time reduction
    5 days
    First autodermoplasty

    Source sentences

    Summary
    It allowed to shorten the terms of the first autodermoplasty at an average by 5 days and to make staying of burned patients at the hospital 11 days shorter.
    1 context sentence
    Summary · context
    The authors share their experiences with treatment of 32 patients with burns of the III-IV degrees using an immunomodulator Thymalin which promoted liquidation of the syndrome of disseminated intravascular coagulation
  6. 06HumanCase report or seriesEfficacy outcome

    In patients with severe burns, thymalin treatment was associated with 11 days shorter hospital stay.

    In plain wordsIn patients with severe burns, thymalin treatment was linked to 11 days shorter hospital stay.

    Peptide
    Thymalin
    Outcome
    DecreaseHospital stay
    Study

    n = 32

    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    Dose not stated

    Measurements

    Hospital stay reduction
    11 days
    Burn patients

    Source sentences

    Summary
    It allowed to shorten the terms of the first autodermoplasty at an average by 5 days and to make staying of burned patients at the hospital 11 days shorter.
    1 context sentence
    Summary · context
    The authors share their experiences with treatment of 32 patients with burns of the III-IV degrees using an immunomodulator Thymalin which promoted liquidation of the syndrome of disseminated intravascular coagulation

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.